Mantle cell lymphoma (MCL) is a B-cell malignancy and often an incurable disease. Novel targeted therapeutics are poised to significantly change the natural history of this disease. The combination of ibrutinib and venetoclax ...

The p53 protein is a transcription factor and has been considered as a master tumour suppressor. TP53 gene is frequently mutated in human cancers (more than 50%). Mutation in p53 not only loses its tumour suppressive ...

The nucleolus is a multifunctional organelle known as the central hub for ribosome biogenesis. Now, it is widely accepted that nucleolus also serves non-canonical role as a stress sensor, responding to numerous internal ...

A prominent theme in malignant transformation is abnormal regulation of epigenetic processes that facilitate gene expression profiles underpinning malignant initiation and progression. The plasticity of the epigenome lends ...

Melanoma is an aggressive cancer with extremely unfavourable prognosis. Two main types of melanoma include cutaneous melanoma (CM) accounting for around 95% and uveal melanoma (UM) around 5%. In Australia, melanoma is in ...

The standard of care for locally advanced rectal cancer (T3-4 +/- N+) is neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME). However, this has been challenged recently with increasing interest ...

Targeting non-transformed stromal components of the tumour microenvironment (TME) has become clinically attractive in treating cancer over the last few decades. On this basis, vascular endothelial growth factor A (VEGFA) ...

Cancer progression is invariably associated with changes in the stromal microenvironment, most notably, the extracellular matrix (ECM) composition. Laminins (LM) are a family of large trimeric ECM proteins comprised of at ...

Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has shown great success in haematological malignancies, leading to recent approval of two CD19-specific CAR T cell products by the Food and Drug Administration ...

Recent studies by our group and others have demonstrated that oncogene- driven hyper-activation of ribosome synthesis and activity is a vulnerability that can be targeted for cancer treatment. Specifically, combined ...